Pathology: metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA); metastatic/advanced RCC (mRCC) - 1st line (L1); metastatic/advanced RCC (mRCC) - 2nd line (L2); mRCC - L1 - PDL1 negative; mRCC - L1 - PDL1 positive;
| metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | metastatic/advanced RCC (mRCC) - 2nd line (L2) | mRCC - L1 - PDL1 negative | mRCC - L1 - PDL1 positive | |||||||||||||||||
| IMmotion-010, 2017 | CheckMate 914, 2017 | KEYNOTE-564, 0 | IMmotion-150 (At - all population), 2018 | IMmotion-150 (AtB - all population), 2018 | IMmotion-151 (all population), 2019 | JAVELIN Renal 101 (all population), 2019 | CheckMate 9ER, 2021 | CheckMate 214 (intermediate and poor risk), 2017 | CheckMate 214 (favorable risk) EXPLORATORY, 2017 | CheckMate 214 (all population), 2017 | KEYNOTE-426, 2019 | KEYNOTE-581/CLEAR (PDL1), 2021 | CONTACT-03, 2023 | CheckMate 025, 2015 | IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019 | IMmotion-150 (At - PDL1>1%), 2018 | IMmotion-150 (AtB - PDL1>1%), 2018 | IMmotion-151 (PDL1 >1%), 2019 | JAVELIN Renal 101( PDL1>1%), 2019 | ||
| atezolizumab plus bevacizumab | 5 | T1 | T1 | T1 | T1 | T1 | |||||||||||||||
| atezolizumab alone | 3 | T1 | T1 | T1 | |||||||||||||||||
| nivolumab plus ipilimumab | 3 | T0 | T1 | T1 | T1 | ||||||||||||||||
| avelumab plus axitinib | 2 | T1 | T1 | ||||||||||||||||||
| nivolumab alone | 2 | T1 | T1 | ||||||||||||||||||
| atezolizumab plus cabozantinib | 1 | T1 | |||||||||||||||||||
| pembrolizumab alone | 1 | T1 | |||||||||||||||||||
| nivolumab plus cabozantinib | 1 | T1 | |||||||||||||||||||
| pembrolizumab plus lenvatinib | 1 | T1 | |||||||||||||||||||
| pembrolizumab plus axitinib | 1 | T1 | |||||||||||||||||||
| cabozantinib | 0 | T0 | |||||||||||||||||||
| placebo | 0 | T0 | T0 | ||||||||||||||||||
| sunitinib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | |||||
| everolimus | 0 | T0 | |||||||||||||||||||